Literature DB >> 16777893

Life without COX 2 inhibitors: risks and benefits are determined by dose and potency.

Enrique J Sánchez-Delgado.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16777893      PMCID： PMC1479663          DOI： 10.1136/bmj.332.7555.1451-b

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.

Authors:  Julia Hippisley-Cox; Carol Coupland
Journal:  BMJ       Date:  2005-06-11

2.  Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.

Authors:  Julia Hippisley-Cox; Carol Coupland; Richard Logan
Journal:  BMJ       Date:  2005-12-03

Review 3.  Cyclooxygenase inhibition and cardiovascular risk.

Authors:  Elliott M Antman; David DeMets; Joseph Loscalzo
Journal:  Circulation       Date:  2005-08-02       Impact factor: 29.690

4.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.

Authors:  Patricia M Kearney; Colin Baigent; Jon Godwin; Heather Halls; Jonathan R Emberson; Carlo Patrono
Journal:  BMJ       Date:  2006-06-03
  4 in total
  1 in total

Review 1.  Non-steroidal anti-inflammatory drugs in the pharmacological management of osteoarthritis in the very old: prescribe or proscribe?

Authors:  Christian Cadet; Emmanuel Maheu
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-06-18       Impact factor: 5.346
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.